Decentralised clinical trials case studies
How our end-to-end services, operational model and technology delivers customised solutions
We are deploying decentralised clinical trials on a global basis in multiple therapeutic areas to support you in navigating the assessment, planning and execution for better outcomes.
Hybrid clinical trial model in a Lupus Nephritis study
The sponsor contracted ICON to conduct a randomised trial using a traditional site-based approach to identify the target dose and investigate the safety, tolerability and efficacy of three doses of an investigative compound administered subcutaneously for the treatment of lupus nephritis.
Fully decentralised clinical trial in heart failure
ICON was approached by a large pharmaceutical company to conduct a fully decentralised placebo-controlled trial, focused
on demonstrating that the drug reduced symptom burden in patients with heart failure.
on demonstrating that the drug reduced symptom burden in patients with heart failure.
Hybrid decentralised clinical trial in Cell Gene Therapy
A biotech company contracted ICON to conduct a large phase 3 study in Cell Gene Therapy (CGT) involving 532 patients.